Prenetics CEO and CFO buy $1 million in shares after Q2 results
Danny Yeung and Brian Rosin purchased shares between August 20 and 25, 2026, bringing leadership's cumulative investment since November 2025 to about $3.75 million.
Prenetics Global Limited disclosed in a Form 6-K filed August 26, 2026 that Chief Executive Officer Danny Yeung and Chief Financial Officer Brian Rosin completed open market purchases of the company's ordinary shares between August 20 and August 25, 2026, within the company's open trading window following the release of second quarter 2026 financial results.1 The two executives together bought $1.0 million of shares.1
Combined with roughly $1.45 million in purchases made in November 2025 and about $1.30 million in February 2026, leadership has now put approximately $3.75 million of personal money into company shares since November 2025, without selling any shares during that span.1
Individually, Yeung bought 24,681 shares for about $502,000 at an average price near $20.34 per share, across trades on August 20 and August 24, 2026.1 That brings his total personal investment to roughly $1.75 million since November 2025.1 Rosin bought 23,100 shares for about $498,000 at an average price near $21.54 per share on August 24 and August 25, 2026, marking his first open-market purchase since joining the company in May 2026.1
The purchases followed second quarter results announced August 18, 2026. According to the filing, the company posted total quarterly revenue that rose sharply from a year earlier, driven by growth in its IM8 nutrition brand, which the filing said had its sixth straight record quarter. IM8 generated $20.9 million of revenue in July alone, reaching an annualized run rate near $251 million, and the company reported its first month of positive consolidated Adjusted Free Cash Flow.1 Prenetics also lifted its full year 2026 revenue outlook to a range of $220 million to $230 million and issued initial 2027 guidance of more than $400 million.1
Yeung's statement cited a July commitment of $1 billion in growth financing to IM8 from General Catalyst's Customer Value Fund.1 The filing defines the company's non-IFRS Adjusted Free Cash Flow metric as net cash from operating activities combined with net fundings received under the General Catalyst Customer Value Fund facility.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.